Patients with Stage III-IVB Head and Neck Cancer

Status: open

18-029 - NRG-HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

Treatment for Head / Neck Cancer

Contact Us Or call (251) 445-9834

Description

This randomized phase II/III trial studies how well radiation therapy works with durvalumab or cetuximab in treating patients with stage III-IVB head and neck cancer who cannot take cisplatin. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Monoclonal antibodies, such as durvalumab and cetuximab, may interfere with the ability of tumor cells to grow and spread. It is not known if radiation therapy with durvalumab will work better than the usual therapy of radiation therapy with cetuximab in treating patients with head and neck cancer. IRB Number 18-029

Sponsors

This trial is sponsored by NRG.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.